» Articles » PMID: 24700732

Analysis of TP53 Mutation Status in Human Cancer Cell Lines: a Reassessment

Overview
Journal Hum Mutat
Specialty Genetics
Date 2014 Apr 5
PMID 24700732
Citations 123
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-derived cell lines play an important role in the investigation of tumor biology and genetics. Across a wide array of studies, they have been tools of choice for the discovery of important genes involved in cancer and for the analysis of the cellular pathways that are impaired by diverse oncogenic events. They are also invaluable for screening novel anticancer drugs. The TP53 protein is a major component of multiple pathways that regulate cellular response to various types of stress. Therefore, TP53 status affects the phenotype of tumor cell lines profoundly and must be carefully ascertained for any experimental project. In the present review, we use the 2014 release of the UMD TP53 database to show that TP53 status is still controversial for numerous cell lines, including some widely used lines from the NCI-60 panel. Our analysis clearly confirms that, despite numerous warnings, the misidentification of cell lines is still present as a silent and neglected issue, and that extreme care must be taken when determining the status of p53, because errors may lead to disastrous experimental interpretations. A novel compendium gathering the TP53 status of 2,500 cell lines has been made available (http://p53.fr). A stand-alone application can be used to browse the database and extract pertinent information on cell lines and associated TP53 mutations. It will be updated regularly to minimize any scientific issues associated with the use of misidentified cell lines (http://p53.fr).

Citing Articles

Small molecule inhibition of ubiquitin C-terminal hydrolase L1 alters cell metabolism proteins and exerts anti- or pro-tumorigenic effects contingent upon chemosensitivity status in high grade serous ovarian cancer.

Jansen C, McAdams J, Kim C, De La Cruz P, Salaverria A, DaSilva N Front Pharmacol. 2025; 16:1547164.

PMID: 40078282 PMC: 11897294. DOI: 10.3389/fphar.2025.1547164.


Breast cancer preclinical models: a vital resource for comprehending disease mechanisms and therapeutic development.

Kaur R, Sharma A, Wijekoon N EXCLI J. 2025; 24:267-285.

PMID: 40071025 PMC: 11895054. DOI: 10.17179/excli2024-7973.


Exploiting Cancer Dormancy Signaling Mechanisms in Epithelial Ovarian Cancer Through Spheroid and Organoid Analysis.

Tomas E, Valdes Y, Davis J, Kolendowski B, Buensuceso A, DiMattia G Cells. 2025; 14(2).

PMID: 39851561 PMC: 11764263. DOI: 10.3390/cells14020133.


PPM1D/Wip1 is amplified, overexpressed, and mutated in human non-Hodgkin's lymphomas.

Pilevneli H, Doger F, Karagenc L, Kozaci D, Kilic Eren M Mol Biol Rep. 2024; 51(1):1115.

PMID: 39489796 DOI: 10.1007/s11033-024-10029-2.


The oncogenic ADAMTS1-VCAN-EGFR cyclic axis drives anoikis resistance and invasion in renal cell carcinoma.

Wen Y, Lin Y, Ho K, Yang Y, Lai F, Chu C Cell Mol Biol Lett. 2024; 29(1):126.

PMID: 39333870 PMC: 11429190. DOI: 10.1186/s11658-024-00643-0.


References
1.
Gazdar A, Girard L, Lockwood W, Lam W, Minna J . Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst. 2010; 102(17):1310-21. PMC: 2935474. DOI: 10.1093/jnci/djq279. View

2.
MacLeod R, Dirks W, Drexler H . Persistent use of misidentified cell lines and its prevention. Genes Chromosomes Cancer. 2001; 33(1):103-5. DOI: 10.1002/gcc.1217. View

3.
Tada M, Iggo R, Ishii N, Shinohe Y, Sakuma S, Estreicher A . Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay. Int J Cancer. 1996; 67(3):447-50. DOI: 10.1002/(SICI)1097-0215(19960729)67:3<447::AID-IJC22>3.0.CO;2-3. View

4.
Isaacs W, Carter B, Ewing C . Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 1991; 51(17):4716-20. View

5.
Liscovitch M, Ravid D . A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett. 2006; 245(1-2):350-2. DOI: 10.1016/j.canlet.2006.01.013. View